Literature DB >> 8585863

Effects of anesthesia and K+ ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium.

M V Cohen1, K S Snell, A Tsuchida, D G Van Wylen, J M Downey.   

Abstract

Glibenclamide, a K+ ATP channel antagonist, blocks the anti-infarct effect of ischemic preconditioning in rabbits, but only when the latter are anesthetized with ketamine-xylazine. Furthermore, the protection triggered by pinacidil, a K+ ATP channel opener, can be aborted by treatment with the adenosine antagonist 8-(P-sulfophenyl)theophylline. This study tests whether either the anesthetic regimen or glibenclamide affects infarct size by modulating interstitial adenosine levels. Interstitial adenosine and total purine concentrations were assessed in open-chest rabbits by the microdialysis technique. Dialysis fibers were inserted into myocardium served by a coronary artery branch surrounded by a snare. All animals sustained a 30-min coronary occlusion and then 120-min reperfusion. Rabbits were anesthetized with either sodium pentobarbital or a ketamine-xylazine mixture. Half of the latter animals also received glibenclamide. The control levels of adenosine in the dialysate were comparable in the three groups, as were those of total purines, and the infusion of glibenclamide caused no change. Ischemia led to 10- to 20-fold increases in interstitial adenosine and 10- to 40-fold rises in total purine concentrations. These increases were equivalent in all groups. Further-more, infarct size as a percentage of the myocardium at risk was also comparable in the three groups. Neither the anesthetic agent nor glibenclamide appears to modulate interstitial adenosine release from ischemic tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585863     DOI: 10.1007/bf00788503

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  32 in total

1.  An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning.

Authors:  J M Downey
Journal:  Cardiovasc Res       Date:  1993-09       Impact factor: 10.787

2.  Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia.

Authors:  D G Van Wylen
Journal:  Circulation       Date:  1994-05       Impact factor: 29.690

3.  Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

Authors:  C F Toombs; T L Moore; R J Shebuski
Journal:  Cardiovasc Res       Date:  1993-04       Impact factor: 10.787

4.  Preconditioning protects ischemic rabbit heart by protein kinase C activation.

Authors:  K Ytrehus; Y Liu; J M Downey
Journal:  Am J Physiol       Date:  1994-03

5.  A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels.

Authors:  Z Yao; G J Gross
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

6.  Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts.

Authors:  J D Thornton; C S Thornton; D L Sterling; J M Downey
Journal:  Circ Res       Date:  1993-01       Impact factor: 17.367

7.  Polymyxin B has multiple blocking actions on the ATP-sensitive potassium channel in insulin-secreting cells.

Authors:  E A Harding; J H Jaggar; P E Squires; M J Dunne
Journal:  Pflugers Arch       Date:  1994-01       Impact factor: 3.657

8.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

9.  Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium.

Authors:  Y Liu; K Ytrehus; J M Downey
Journal:  J Mol Cell Cardiol       Date:  1994-05       Impact factor: 5.000

10.  Myocardial protection with preconditioning.

Authors:  G C Li; J A Vasquez; K P Gallagher; B R Lucchesi
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.